Impacto económico de la introducción de la vacuna inactivada inyectable contra la poliomielitis en Colombia
Bibliographic Data
| ID | 14966810 |
|---|---|
| Authors | Nelson Alvis-Guzman (0000-0001-9458-864X, University of Cartagena), Nelson Alvis, Fernando De La Hoz (0000-0001-9436-7935, Universidad Nacional de Colombia), J Narváez (0000-0002-3057-7914, Universidad Nacional de Colombia) |
| Year | 2010 |
| Volume | 27 |
| Issue | 5 |
| Pages | 352-359 |
| Publication date | 2010-05-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Revista Panamericana de Salud Pública (JOURNAL) |
| Journal identifiers | ISSN: 1020-4989 • E-ISSN: 1680-5348 |
| Publisher | FapUNIFESP (SciELO) (PUBLISHER) |
| DOI | 10.1590/s1020-49892010000500005 |
| PMID | 20602069 |
| OpenAlex | W2139026144 |
| SciELO | S1020-49892010000500005 |
| Language | ES |
| Citations received | 2 |
| References cited | 4 |
OBJECTIVE: Evaluate the cost-effectiveness of introducing the injectable inactivated polio vaccine (IPV) in Colombia versus the current system based on the use of the oral vaccine (OPV). METHODS: A Markov model was designed, based on a hypothetical cohort of newborns that would receive the IPV or the OPV vaccine, with a two-year follow-up and monthly estimates of the number of cases of vaccine-associated paralytic poliomyelitis (VAPP) that would emerge. The cost was analyzed from the perspective of the insurer (costs throughout life) and society (cases of VAPP and disability-adjusted life years [DALYs] prevented). RESULTS: From 1988 to 1998, some 22.5 million doses of OVP were administered in Colombia and nine cases of VAPP were detected, for a rate of 4.0 yen 10-7 dose. According to the model, 2 to 4 cases of VAPP could be anticipated in the following two years. The cost of treating the VAPP cases would total US$302,008, with the cost of vaccination with OPV coming to US$737,037 and with IPV, US$5,527,777. Vaccination with IPV would prevent 64 DALYs, at a cost of US$71,062 per DALY prevented; preventing one case of VAPP by substituting OPV with IPV would cost between US$1.8 and US$2.2 million. CONCLUSIONS: Substituting OPV with IPV is not a cost-effective measure in Colombia, even if the cellular vaccine against whooping cough currently in use were replaced with an acellular vaccine combined with an IPV
Cost effectiveness · Disability-adjusted life year · Disease burden · Environmental health · Population · Vaccination · Diphtheria, Corynebacterium, and Tetanus · Immunodeficiency and Autoimmune Disorders · Medicine · Viral Infections and Immunology Research · Pediatrics · Virology
| Citations per year | 0.18 |
|---|---|
| Citation span | 2015 - 2022 (8) |
| Highly cited | No |